The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+T lymphocytes
Open accessAbstract
Many human and mouse tumor antigens are normal, nonmutated tissue differentiation antigens. Consequently, immunization with these “self” antigens could induce autoimmunity. When we tried to induce immune responses to five mouse melanocyte differentiation antigens, gp100, MART-1, tyrosinase, and tyrosinase-related proteins (TRP) 1 and TRP-2, we observed striking depigmentation and melanocyte destruction only in the skin of mice inoculated with a vaccinia virus encoding mouse TRP-1. These mice rejected a lethal challenge of B16 melanoma, indicating the immune response against TRP-1 could destroy both normal and malignant melanocytes. Cytotoxic T lymphocytes specific for TRP-1 could not be detected in depigmented mice, but high titers of IgG anti-TRP-1 antibodies were present. Experiments with knockout mice revealed an absolute dependence on major histocompatibility complex class II, but not major histocompatibility complex class I, for the induction of both vitiligo and tumor protection. Together, these results suggest that the deliberate induction of self-reactivity using a recombinant viral vector can lead to tumor destruction, and that in this model, CD4+T lymphocytes are an integral part of this process. Vaccine strategies targeting tissue differentiation antigens may be valuable in cancers arising from nonessential cells and organs such as melanocytes, prostate, testis, breast, and ovary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The expanding universe of T-cell subsets: Th1, Th2 and more
Mosmann, T. R., & Sad, S. (1996) · Immunology Today · doi:10.1016/0167-5699(96)80606-2 · Cited by 3,633
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,639
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Ridge, J. P., Di Rosa, F., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,342
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
Self-citationWalter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., & Riddell, S. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510193331603 · Cited by 1,771
Current Protocols in Molecular Biology
(2018) · Current Protocols in Molecular Biology · doi:10.1002/(issn)1934-3647 · Cited by 1,372
Immunity to Methylcholanthrene-Induced Sarcomas
(1957) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,229
Romagnani, S. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)80019-9 · Cited by 1,078
β2-Microglobulin deficient mice lack CD4−8+ cytolytic T cells
Zijlstra, M., Bix, M., Simister, N. E., Loring, J. M., Raulet, D. H., & Jaenisch, R. (1990) · Nature · doi:10.1038/344742a0 · Cited by 1,012
Cited by
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Self-citationA2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,065
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
Self-citationTumor-specific Th17-polarized cells eradicate large established melanoma
Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 845
Self-citationExploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810
Antony, P. A., Piccirillo, C. A., Akpinarli, A., Finkelstein, S. E., Speiss, P. J., Surman, D. R., Palmer, D. C., Chan, C.-C., Klebanoff, C. A., Overwijk, W. W., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2591 · Cited by 760
Self-citationAdoptive-cell-transfer therapy for the treatment of patients with cancer
Dudley, M. E., & Rosenberg, S. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1167 · Cited by 660
Self-citationCancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1150 · Cited by 636
Klebanoff, C. A., Khong, H. T., Antony, P. A., Palmer, D. C., & Restifo, N. P. (2005) · Trends in Immunology · doi:10.1016/j.it.2004.12.003 · Cited by 469
Self-citationB16 as a Mouse Model for Human Melanoma
Overwijk, W. W., & Restifo, N. P. (2000) · Current Protocols in Immunology · doi:10.1002/0471142735.im2001s39 · Cited by 434
Self-citationMelanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma
Yee, C., Thompson, J. A., Roche, P., Byrd, D. R., Lee, P. P., Piepkorn, M., Kenyon, K., Davis, M. M., Riddell, S. R., & Greenberg, P. D. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.11.1637 · Cited by 428
Yang, Y., Huang, C.-T., Huang, X., & Pardoll, D. M. (2004) · Nature Immunology · doi:10.1038/ni1059 · Cited by 425
Bronte, V., Chappell, D. B., Apolloni, E., Cabrelle, A., Wang, M., Hwu, P., & Restifo, N. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5728 · Cited by 405
Self-citationThe Makings of a Tumor Rejection Antigen
Gilboa, E. (1999) · Immunity · doi:10.1016/s1074-7613(00)80101-6 · Cited by 381
Combination immunotherapy: a road map
Ott, P. A., Hodi, F. S., Kaufman, H. L., Wigginton, J. M., & Wolchok, J. D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0218-5 · Cited by 374
Spinning molecular immunology into successful immunotherapy
Pardoll, D. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri774 · Cited by 360
Eradication of Established Tumors by CD8+ T Cell Adoptive Immunotherapy
Hanson, H. L., Donermeyer, D. L., Ikeda, H., White, J. M., Shankaran, V., Old, L. J., Shiku, H., Schreiber, R. D., & Allen, P. M. (2000) · Immunity · doi:10.1016/s1074-7613(00)00026-1 · Cited by 358
Cancer therapy using a self-replicating RNA vaccine
Ying, H., Zaks, T. Z., Wang, R.-F., Irvine, K. R., Kammula, U. S., Marincola, F. M., Leitner, W. W., & Restifo, N. P. (1999) · Nature Medicine · doi:10.1038/10548 · Cited by 322
Self-citationvan Elsas, A., Sutmuller, R. P. M., Hurwitz, A. A., Ziskin, J., Villasenor, J., Medema, J.-P., Overwijk, W. W., Restifo, N. P., Melief, C. J. M., Offringa, R., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.481 · Cited by 309
Self-citationT cell homeostatic proliferation elicits effective antitumor autoimmunity
Dummer, W., Niethammer, A. G., Baccalà, R., Lawson, B. R., Wagner, N., Reisfeld, R. A., & Theofilopoulos, A. N. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15175 · Cited by 308
Human tumor antigens for cancer vaccine development
Wang, R., & Rosenberg, S. A. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01331.x · Cited by 296
Self-citationT cell homeostatic proliferation elicits effective antitumor autoimmunity
Dummer, W., Niethammer, A. G., Baccala, R., Lawson, B. R., Wagner, N., Reisfeld, R. A., & Theofilopoulos, A. N. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215175 · Cited by 270
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways
Leitner, W. W., Hwang, L. N., deVeer, M. J., Zhou, A., Silverman, R. H., Williams, B. R. G., Dubensky, T. W., Ying, H., & Restifo, N. P. (2003) · Nature Medicine · doi:10.1038/nm813 · Cited by 269
Self-citationThe promise of cancer vaccines
Gilboa, E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1359 · Cited by 267
The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity
Wang, R.-F. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)01896-8 · Cited by 266
Cytotoxic T cell immunity against telomerase reverse transcriptase in humans
Minev, B., Hipp, J., Firat, H., Schmidt, J. D., Langlade-Demoyen, P., & Zanetti, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.070560797 · Cited by 255
Sitkovsky, M. V., Kjaergaard, J., Lukashev, D., & Ohta, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0229 · Cited by 253
Ludewig, B., Ochsenbein, A. F., Odermatt, B., Paulin, D., Hengartner, H., & Zinkernagel, R. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.795 · Cited by 252
Metadata
- Authors
- Overwijk, W. W., Lee, D. S., Surman, D. R., Irvine, K. R., Touloukian, C. E., Chan, C.-C., Carroll, M. W., Moss, B., Rosenberg, S. A., & Restifo, N. P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-03-16
- Volume
- 96
- Issue
- 6
- Pages
- 2982-2987
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2107629538
- Cited by
- 381
- References
- 41
- FWCI
- 14.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.